Literature DB >> 12187390

High-density lipoprotein apolipoprotein A-I kinetics in obese insulin resistant patients. An in vivo stable isotope study.

F Pont1, L Duvillard, E Florentin, P Gambert, B Vergès.   

Abstract

AIMS/HYPOTHESIS: Mechanisms responsible for the decreased high-density lipoprotein (HDL) cholesterol level associated with insulin resistance in obese patients are not clearly understood. To determine the influence of insulin resistance at an early stage on HDL metabolism, we performed a stable isotope kinetic study of apolipoprotein (apo) A-I, in five obese insulin resistant women with normal fasting triglycerides and without impaired glucose tolerance, and in five age-matched control women.
METHODS: Each subject received a 16 h constant infusion of L-[1-(13)C]leucine at 0.7 mg/kg/h following a primed bolus of 0.7 mg/kg.
RESULTS: ApoA-I fractional catabolic rate (FCR) was significantly increased in insulin-resistant women compared to controls (0.316+/-0.056 vs 0.210+/-0.040 per day, P<0.01), indicating a significant 50% increase of apoA-I catabolism, leading to an important reduction of plasma apoA-I residence time (3.25+/-0.59 vs 4.92+/-1.11, P<0.01). ApoA-I production rate tended to be higher in insulin resistant women than in controls (364+/-77 vs 258+/-60 mg/l/day, P=0.13), but the difference was not statistically significant. ApoA-I FCR was correlated with triglycerides during the fed state (r=0.69; P=0.026) and HDL triglycerides-esterified cholesterol ratio (r=0.73; P=0.016), suggesting that alteration of apoA-I metabolism in insulin resistance may be partly related to HDL enrichment in triglycerides.
CONCLUSIONS: Our kinetic study shows that patients, at an early stage of insulin resistance (without impaired glucose tolerance nor fasting hypertriglyceridaemia), already have a significant alteration of apoA-I metabolism (increased apoA-I catabolism), which is consistent with the increased risk of atherosclerosis in this population.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12187390     DOI: 10.1038/sj.ijo.0802070

Source DB:  PubMed          Journal:  Int J Obes Relat Metab Disord


  17 in total

Review 1.  The emerging role of HDL in glucose metabolism.

Authors:  Brian G Drew; Kerry-Anne Rye; Stephen J Duffy; Philip Barter; Bronwyn A Kingwell
Journal:  Nat Rev Endocrinol       Date:  2012-01-24       Impact factor: 43.330

Review 2.  Studying apolipoprotein turnover with stable isotope tracers: correct analysis is by modeling enrichments.

Authors:  Rajasekhar Ramakrishnan
Journal:  J Lipid Res       Date:  2006-09-01       Impact factor: 5.922

3.  Changes in glucose metabolism and mRNA expression of IRS-2 in rats exposed to phoxim and the protective effects of vitamin E.

Authors:  Jing Zhang; Wentao Song; Yuecheng Sun; Baojing Cheng; Anshan Shan
Journal:  Toxicol Res (Camb)       Date:  2017-12-01       Impact factor: 3.524

4.  The Effects of 3 Weeks of Uphill and Downhill Walking on Blood Lipids and Glucose Metabolism in Pre-Diabetic Men: A Pilot Study.

Authors:  Marc Philippe; Hannes Gatterer; Erika Maria Eder; Alexander Dzien; Matthias Somavilla; Andreas Melmer; Christoph Ebenbichler; Tom Müller; Martin Burtscher
Journal:  J Sports Sci Med       Date:  2017-03-01       Impact factor: 2.988

5.  Hyperuricemia is Associated with Increased Apo AI Fractional Catabolic Rates and Dysfunctional HDL in New Zealand Rabbits.

Authors:  Miriam Martínez-Ramírez; Cristóbal Flores-Castillo; L Gabriela Sánchez-Lozada; Rocío Bautista-Pérez; Elizabeth Carreón-Torres; José Manuel Fragoso; José Manuel Rodriguez-Pérez; Fernando E García-Arroyo; Victoria López-Olmos; María Luna-Luna; Gilberto Vargas-Alarcón; Martha Franco; Oscar Pérez-Méndez
Journal:  Lipids       Date:  2017-09-22       Impact factor: 1.880

6.  Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes.

Authors:  B Vergès; E Florentin; S Baillot-Rudoni; S Monier; J M Petit; D Rageot; P Gambert; L Duvillard
Journal:  Diabetologia       Date:  2008-06-05       Impact factor: 10.122

7.  Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies.

Authors:  Dick C Chan; P Hugh R Barrett; Gerald F Watts
Journal:  Clin Biochem Rev       Date:  2004-02

8.  When HDL gets fat...

Authors:  Robert J Brown; Daniel J Rader
Journal:  Circ Res       Date:  2008-07-18       Impact factor: 17.367

9.  Glycation Reduces the Stability of ApoAI and Increases HDL Dysfunction in Diet-Controlled Type 2 Diabetes.

Authors:  Sangeeta R Kashyap; Abdullah Osme; Serguei Ilchenko; Makan Golizeh; Kwangwon Lee; Shuhui Wang; James Bena; Stephen F Previs; Jonathan D Smith; Takhar Kasumov
Journal:  J Clin Endocrinol Metab       Date:  2018-02-01       Impact factor: 5.958

10.  Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes.

Authors:  Bruno Vergès; Emmanuel Florentin; Sabine Baillot-Rudoni; Jean-Michel Petit; Marie Claude Brindisi; Jean-Paul Pais de Barros; Laurent Lagrost; Philippe Gambert; Laurence Duvillard
Journal:  J Lipid Res       Date:  2009-01-22       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.